Single-arm, Multi-center, Prospective Clinical Study of Recombinant Human Endostatin Combined with Afatinib and Teggio in Second-line Treatment of Advanced Lung Squamous Cell Carcinoma
10.13748/j.cnki.issn1007-7693.20231829
- VernacularTitle:重组人血管内皮抑制素联合阿法替尼及替吉奥二线治疗晚期肺鳞癌的单臂、多中心、前瞻性临床研究
- Author:
Yang CHEN
1
;
Guodong FAN
1
;
Annan JIAO
1
;
Zegeng LI
1
;
Jiabing TONG
1
;
Biao FANG
2
;
Suling YAO
3
;
Mingqi WANG
1
;
Mei ZHANG
1
;
Ping LI
1
Author Information
1. Department of Oncology, The First Affiliated Hospital of Anhui Medical University, Hefei 230022, China
2. Jingxian Hospital of Traditional Chinese Medicine, Xuancheng 242500, China
3. Mingguang Hospital of Traditional Chinese Medicine, Mingguang 239400, China
- Publication Type:Journal Article
- Keywords:
lung squamous cell carcinoma；recombinant human endostatin；afatinib；teggio；second-line treatment
- From:
Chinese Journal of Modern Applied Pharmacy
2024;41(10):1388-1393
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE :To evaluate the effictiveness and safety of recombinant human endostatin combined with afatinib and teggio in the treatment of advanced lung squamous cell carcinoma.
METHODS
A total of 25 patients with driver-negative advanced lung squamous cell carcinoma were included in this single-arm prospective study, and the enrolled patients were treated with recombinant human endostatin combined with afatinib and teggio as scheduled. Progression-free survival(PFS), overall survival(OS), disease control rate(DCR), objective response rate(ORR), and adverse reactions(AR) were observed and analyzed.
RESULTS
The 25 enrolled patients received at least 2 cycles of second-line treatment, and were followed up as of March 31, 2023. Among them, 4 patients had partial remission, 17 patients had stable disease, and 4 patients experienced progressive disease. The ORR confirmed by the researchers was 16%(95%CI, 4.5%−36.1%), DCR was 84%(95%CI, 63.9%−95.5%), and median PFS was 5.3 months(95%CI, 3.5−6.9 months). The median OS had not yet been achieved. The entire group of patients had good treatment tolerance, and the most common level Ⅲ or Ⅳ adverse events related to treatment were leukopenia(20%) and rash(12%), with no reported treatment-related deaths.
CONCLUSION
Recombinant human endostatin combined with afatinib and teggio in the second line treatment of advanced lung squamous cell carcinoma can prolong the progression free survival period of patients and is relatively safe, which is worth further exploration and promotion.
